Low-molecular-weight iron complexes and oxygen radical reactions in idiopathic haemochromatosis

1985 ◽  
Vol 68 (4) ◽  
pp. 463-467 ◽  
Author(s):  
J. M. C. Gutteridge ◽  
D. A. Rowley ◽  
E. Griffiths ◽  
B. Halliwell
Keyword(s):  
Molecular Weight ◽  
Iron Overload ◽  
Membrane Lipids ◽  
Iron Complexes ◽  
Iron Chelator ◽  
Oxygen Radical ◽  
Radical Reactions ◽  
Low Molecular Weight ◽  
Iron Salts ◽  
Low Molecular Weight Iron

1. The sera of patients with idiopathic haemochromatosis and iron-overload have been found to contain low-molecular-weight iron complexes detectable in the ‘bleomycin assay'. 2. These complexes stimulate both the peroxidation of membrane lipids and the formation of the highly reactive and damaging hydroxyl radical. 3. The iron chelator desferrioxamine interferes with these reactions. 4. We suggest that oxygen radical reactions stimulated by iron salts are important in the pathology of idiopathic haemochromatosis.

Acute iron overload: the role of spermine as endogenous low molecular weight iron chelator

2001 ◽  
Vol 34 ◽  
pp. 47-48 ◽  
Author(s):  
D.D. Pavlović ◽  
G. Kocić ◽  
G. Bjelaković ◽  
D. Sokolović ◽  
B. Djindjić
Keyword(s):  
Molecular Weight ◽  
Iron Overload ◽  
Iron Chelator ◽  
Low Molecular Weight ◽  
Low Molecular Weight Iron

Increased prooxidant action of hepatic cytosolic low-molecular-weight iron in experimental iron overload

Hepatology ◽  
1990 ◽  
Vol 11 (6) ◽  
pp. 1038-1043 ◽  
Author(s):  
Robert S. Britton ◽  
Marco Ferrali ◽  
Christopher J. Magiera ◽  
Richard O. Recknagel ◽  
Bruce R. Bacon
Keyword(s):  
Molecular Weight ◽  
Iron Overload ◽  
Low Molecular Weight ◽  
Prooxidant Action ◽  
Low Molecular Weight Iron

In vivo behaviour of low molecular weight iron complexes

1991 ◽  
Vol 16 (3) ◽  
pp. 203-206 ◽  
Author(s):  
L. J. Anghileri ◽  
A. Cordova Martinez ◽  
P. Maincent ◽  
J. Robert
Keyword(s):  
Molecular Weight ◽  
Iron Complexes ◽  
Low Molecular Weight ◽  
Low Molecular Weight Iron

scholarly journals Superoxide-dependent formation of hydroxyl radicals and lipid peroxidation in the presence of iron salts. Detection of ‘catalytic’ iron and anti-oxidant activity in extracellular fluids

1982 ◽  
Vol 206 (3) ◽  
pp. 605-609 ◽  
Author(s):  
John M. C. Gutteridge ◽  
David A. Rowley ◽  
Barry Halliwell
Keyword(s):  
Lipid Peroxidation ◽  
Molecular Weight ◽  
Hydroxyl Radicals ◽  
Oxygen Radical ◽  
Low Ph ◽  
Radical Reactions ◽  
Iron Catalysts ◽  
Ph Values ◽  
Iron Salts ◽  
Anti Oxidant

Synovial fluid from rheumatoid patients and normal cerebrospinal fluid contains micromolar concentrations of non-protein-bound iron salts that can promote lipid peroxidation and also the superoxide-dependent formation of hydroxyl radicals from hydrogen peroxide. These iron catalysts of oxygen radical reactions cannot be detected by conventional assays unless interfering high-molecular-weight substances, probably proteins, are removed by ultrafiltration or inactivated by exposure to low pH values. The bleomycin assay for ‘catalytic’ iron [Gutteridge, Rowley & Halliwell (1981) Biochem. J.199, 263–265] does not suffer from these artifacts.

Therapeutic Macromolecular Iron Chelators

2019 ◽  
Vol 26 (2) ◽  
pp. 323-334 ◽  
Author(s):  
Upendra Bulbake ◽  
Alka Singh ◽  
Abraham J. Domb ◽  
Wahid Khan
Keyword(s):  
Iron Overload ◽  
Chelation Therapy ◽  
Iron Chelator ◽  
Therapeutic Agents ◽  
Iron Chelators ◽  
Low Molecular Weight ◽  
Research Findings ◽  
Pharmaceutical Properties ◽  
Single Living ◽  
Living Process

Iron is a key element for every single living process. On a fundamental level, targeting iron is a valuable approach for the treatment of disorders caused by iron overload. Utilizing iron chelators as therapeutic agents has received expanding consideration in chelation therapy. Approved low molecular weight (MW) iron chelators to treat iron overload may experience short half-lives and toxicities prompting moderately high adverse effects. In recent years, polymeric/macromolecular iron chelators have received attention as therapeutic agents. Polymeric iron chelators show unique pharmaceutical properties that are different to their conventional small molecule counterparts. These polymeric iron chelators possess longer plasma half-lives and reduced toxicities, thus exhibiting a significant supplement to currently using low MW iron chelator therapy. In this review, we have briefly discussed polymeric iron chelators and factors to be considered when designing clinically valuable iron chelators. We have also discussed applications of polymeric iron chelators in the diseases caused by iron overload associated with transfusional hemosiderosis, neurodegenerative disorders, malaria and cancer. With this, research findings for new polymeric iron chelators are also covered.

Sign in / Sign up

Export Citation Format

Share Document